Score: 81/100 | MI:9 TR:8 N:7 DI:9 RE:8 CE:8 TE:8 EB:8 AU:8 TP:8
Experiment Overview
flowchart TD
experiments_dlb_alpha_synuclei["Alpha-Synuclein Staging and Spreading in DLB S"]
style experiments_dlb_alpha_synuclei fill:#4fc3f7,stroke:#333,color:#000
experiments_dlb_alph_0["Experiment Overview"]
experiments_dlb_alpha_synuclei -->|"includes"| experiments_dlb_alph_0
style experiments_dlb_alph_0 fill:#81c784,stroke:#333,color:#000
experiments_dlb_alph_1["Background and Rationale"]
experiments_dlb_alpha_synuclei -->|"includes"| experiments_dlb_alph_1
style experiments_dlb_alph_1 fill:#ef5350,stroke:#333,color:#000
experiments_dlb_alph_2["Hypothesis"]
experiments_dlb_alpha_synuclei -->|"includes"| experiments_dlb_alph_2
style experiments_dlb_alph_2 fill:#ffd54f,stroke:#333,color:#000
experiments_dlb_alph_3["Research Gap Addressed"]
experiments_dlb_alpha_synuclei -->|"includes"| experiments_dlb_alph_3
style experiments_dlb_alph_3 fill:#ce93d8,stroke:#333,color:#000
experiments_dlb_alph_4["Validation Protocol"]
experiments_dlb_alpha_synuclei -->|"includes"| experiments_dlb_alph_4
style experiments_dlb_alph_4 fill:#4fc3f7,stroke:#333,color:#000
experiments_dlb_alph_5["Phase 1: Spatial Mapping of Pathology"]
experiments_dlb_alpha_synuclei -->|"includes"| experiments_dlb_alph_5
style experiments_dlb_alph_5 fill:#81c784,stroke:#333,color:#000
...Score: 81/100 | MI:9 TR:8 N:7 DI:9 RE:8 CE:8 TE:8 EB:8 AU:8 TP:8
Experiment Overview
Mermaid diagram (expand to render)
This study investigates the spatial progression pattern of alpha-synuclein pathology in Dementia with Lewy Bodies brain tissue to determine whether DLB follows a different staging sequence than Parkinson's disease and identify optimal intervention points.
Background and Rationale
Dementia with Lewy Bodies (DLB) is characterized by the abnormal aggregation of alpha-synuclein protein into Lewy bodies and Lewy neurites throughout the brain. While Parkinson's disease (PD) and DLB share common alpha-synuclein pathology, emerging evidence suggests that the spatial distribution and progression patterns differ significantly between these conditions. Understanding these differences is critical for developing disease-modifying therapies that target the propagation mechanism itself.
The prion-like propagation of alpha-synuclein represents one of the most important mechanisms driving disease progression in Lewy body disorders. Pathological alpha-synuclein can spread between connected neurons, templating the misfolding of endogenous protein and propagating pathology throughout the nervous system. This cell-to-cell transmission occurs through multiple mechanisms including exosome release, tunneling nanotubes, synaptic release, and receptor-mediated uptake[@peng2018].
Hypothesis
The staging and spreading pattern of alpha-synuclein pathology in DLB differs from PD in key ways:
Cortical-first pattern — DLB shows earlier cortical involvement than PD
Cholinergic vulnerability — Nucleus basalis of Meynert is affected earlier in DLB
Network propagation — Pathology follows specific functional networks
Co-pathology influence — AD comorbidity (Aβ/tau) modifies spreadingResearch Gap Addressed
DLB Gap #1: What is the spatial staging pattern of alpha-synuclein in DLB and how does it differ from PD?
Despite extensive research on alpha-synuclein propagation in PD, the specific staging pattern in DLB remains poorly characterized. This represents a critical knowledge gap because:
- DLB is the second most common neurodegenerative dementia after Alzheimer's disease
- Current therapeutic approaches do not account for DLB-specific propagation patterns
- Early intervention strategies require precise knowledge of where and when pathology spreads
- The relationship between alpha-synuclein staging and clinical features in DLB is not well understood
Validation Protocol
Phase 1: Spatial Mapping of Pathology
Approach: Characterize alpha-synuclein distribution across brain regions
Model System:
- Postmortem human brain tissue: 40 DLB cases, 40 PD cases, 20 controls
- 12 brain regions per case (brainstem, subcortical, limbic, cortical)
Technique:
- Immunohistochemical mapping of phosphorylated alpha-synuclein (pSer129)[@proudfoot2019]
- Semi-quantitative scoring (0-3) across regions
- Stereological sampling for quantitative analysis
Key Comparisons:
DLB vs PD in same brain region
DLB with vs without AD comorbidity
DLB clinical variants (cortical vs brainstem predominant)Readouts:
- Regional pathology burden (pSer129 load)
- Lewy body density and morphology
- Correlation with clinical features
Phase 2: Network Mapping
Approach: Test network-based propagation hypothesis
Model Systems:
- Human connectome data (HMRI) linked to pathology data
- Retrograde tracing in model systems
- Spatial transcriptomics of affected regions
Tests:
Functional connectivity correlation with pathology burden
Transsynaptic spread patterns
Region-to-region propagation velocityPhase 3: Early Detection Development
Approach: Identify pre-symptomatic markers
Screening:
- Test whether peripheral tissue (skin, Enteric NS) mirrors CNS staging
- Develop PET ligands for early detection
- Validate biomarker correlates
Strain Diversity and Its Implications
The concept of alpha-synuclein strain diversity is central to understanding why DLB and PD produce different clinical phenotypes despite sharing the same underlying protein pathology. Different conformational variants ("strains") of alpha-synuclein fibrils produce distinct disease patterns[@peelaerts2018][@bousset2016]:
| Property | DLB/PD Strain | MSA Strain |
|----------|---------------|------------|
| Fibril structure | Distinct 3D conformation | Different conformation |
| Cellular distribution | Primarily neuronal | Primarily glial |
| Regional pattern | Cortical predominance | White matter preference |
| Clinical phenotype | Dementia, hallucinations | Autonomic failure |
Understanding which strains are predominant in DLB versus PD will inform strain-specific therapeutic approaches.
Co-Pathology Interactions
DLB frequently presents with concurrent Alzheimer disease pathology, which significantly influences the propagation pattern:
Tau Pathology
- Approximately 50-80% of DLB cases have comorbid tau pathology
- Tau pathology may accelerate alpha-synuclein propagation through cross-seeding mechanisms
- Mixed pathology is associated with more severe dementia
Amyloid Pathology
- 50-70% of DLB cases have amyloid plaques
- Amyloid-beta may serve as a nidus for alpha-synuclein aggregation
- Presence of amyloid confounds treatment response predictions
Vascular Pathology
- White matter lesions are common in DLB
- Vascular pathology contributes to cognitive deficits independently
- May impact disease course through multiple mechanisms
Expected Outcomes
Staging system for DLB (distinct from PD)
Network propagation model validated or refuted
AD comorbidity impact on spreading quantified
Early detection targets identified
Intervention window definedTimeline
| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | 12 months | Spatial map complete |
| Phase 2 | 12 months | Network model tested |
| Phase 3 | 12 months | Early detection targets |
Total: 36 months to early intervention targets
Feasibility Assessment
| Factor | Score | Notes |
|--------|-------|-------|
| Technical Feasibility | 8/10 | IHC established; requires tissue collection |
| Model Validity | 9/10 | Human tissue is gold standard |
| Timeline | 36 months | Achievable |
| Cost | $3.2M | Tissue bank major cost |
Cost Breakdown:
- Phase 1: $1.2M (tissue, IHC, imaging)
- Phase 2: $1.0M (connectomics, spatial transcriptomics)
- Phase 3: $1.0M (biomarker development)
Cross-Disease Value
- Findings inform PD staging model
- Applicable to pure DLB vs PD with dementia distinction
- Network model relevant to other synucleinopathies
- Early detection applicable to prodromal DLB
Clinical Correlation Targets
Understanding how alpha-synuclein staging correlates with clinical features is essential for developing biomarkers and therapeutic endpoints:
| Clinical Feature | Expected Staging Correlation |
|------------------|------------------------------|
| Cognitive fluctuations | Variable network spread patterns |
| Visual hallucinations | Occipital cortex involvement |
| Parkinsonism | Substantia nigra pathology load |
| Autonomic dysfunction | Brainstem center involvement |
| REM sleep behavior disorder | Early brainstem spread |
Methodological Considerations
Histopathological Techniques
- Phospho-Ser129 alpha-synuclein immunohistochemistry (primary marker)
- Alpha-synuclein conformational antibodies (OC, MJUKI)
- Thioflavin-S for amyloid co-pathology
- AT8 for tau pathology assessment
Quantitative Approaches
- Stereological cell counting
- Image analysis for area fraction measurements
- Regional pathology burden scoring (0-3 scale)
- Correlation with antemortem clinical data
Controls and Comparisons
- Age-matched neurologically normal controls
- PD without dementia cases
- DLB with/without AD comorbidity
- Early-onset vs late-onset DLB
Risk Mitigation
| Risk | Mitigation Strategy |
|------|---------------------|
| Tissue availability | Establish brain bank partnerships early |
| Technical variability | Standardize IHC protocols across sites |
| Clinical data quality | Retrospective chart review with standardized assessments |
| Stain consistency | Use single antibody lot throughout study |
See Also
- [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
- [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathway-parkinsons)
- [Alpha-Synuclein Prion-Like Propagation in DLB](/mechanisms/alpha-synuclein-prion-like-propagation-dlb)
- [DLB Cognitive Fluctuation Mechanisms](/mechanisms/dlb-cognitive-fluctuation-mechanisms)
- [DLB Cholinergic Dysfunction](/mechanisms/dlb-cholinergic-dysfunction-mechanisms)
References
[Proudfoot M, et al. Alpha-synuclein quaternary structure across the Lewy body disease spectrum (2019)](https://pubmed.ncbi.nlm.nih.gov/30681761/)
[Kim WS, et al. Role of alpha-synuclein in the pathogenesis of multiple system atrophy and Lewy body disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30850862/)
[Peng C, et al. Cell-to-cell transmission of alpha-synuclein aggregates in Lewy body disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29786792/)
[Schweighauser M, et al. Amyloid deposits in multiple system atrophy and Lewy body disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35653491/)
[Peelaerts W, et al. Alpha-Synuclein strains and the diversity of Lewy body disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29843273/)
[Bousset L, et al. Alpha-Synuclein aggregation strains in Lewy body disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27225924/)
[Volpicelli-Daley LA, et al. Formation and transmission of alpha-synuclein oligomers in the brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31214847/)
[Tarutani A, et al. The effect of chaperone-mediated autophagy on alpha-synuclein oligomerization (2018)](https://pubmed.ncbi.nlm.nih.gov/29662221/)